Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/91—Nitro radicals
  • C07D233/92—Nitro radicals attached in position 4 or 5
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/30—Oxygen or sulfur atoms
  • C07D233/32—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/70—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/72—Two oxygen atoms, e.g. hydantoin
  • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/91—Nitro radicals
  • C07D233/92—Nitro radicals attached in position 4 or 5
  • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D249/12—Oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems

Definitions

• the invention relates to substituted Diarylheterocyclen and their physiologically acceptable salts and physiologically functional derivatives.
• the invention therefore relates to compounds of the formula I,
• R11, R12, R13, R14, R15 independently of one another are H, (CC 6 ) -alkyl
• B is a bond or a linker of one or two radicals from the
• R 19, R 20, R 21, R 22, R 23 independently of one another are H, (CC 6 ) -alkyl, aryl;
• R 1 , R 2 , R 3 , R 4 independently of one another are H, F, Cl, Br, J, OH, CF 3 , NO 2 , CN, OCF 3 , O- (C 1 -C 6 ) -alkyl, O- (CC 4 ) alkoxy- (C ⁇ -C4) alkyl, S- (CC 6) alkyl, (CC 6) - alkyl, (C 2 -C 6) alkenyl, (C 3 -C 8) -cycloalkyl, O - (C 3 -C 8) cycloalkyl, (C 3 -C 8) - cycloalkenyl, O- (C 3 -C 8) -CycloalkenyI, (C 2 -C 6) -alkynyl, (C 0 -C 8) Alkylene-aryl, O- (C 0 -C 8 ) -alkylene-aryl, S-aryl, N (R 24
• R24, R25, R26, R27, R28, R30 independently of one another are H, (C 1 -C 6 ) -alkyl
• R29, R31, R32 independently of one another are H, (C 1 -C 4 -alkyl, aryl;
• R5, R6, R7, R8 are independently H, F, Cl, Br, I, OH, CF 3, NO 2, CN, OCF 3> O- (CC 6) -alkyl, O- (C -C 4) - Alkoxy (CC 4 ) alkyl, S (CrC 6 ) alkyl, (d-Ce) alkyl, (C 2 -C 6 ) alkenyl, (C 3 -C 8 ) cycloalkyl, O- (C 3 -C 8) -cycloalkyl, (C 3 -C 8) -cycloalkenyl, O- (C 3 -C 8) -cycloalkenyl, (C 2 -C 6) -alkynyl, (C 0 -C 8) -alkylene- Aryl, O- (C 0 -C 8 ) -alkylene-aryl, S-aryl, N (R 33) (R 34), SO
• R33, R34 independently of one another are H, (C-rC 6 ) -alkyl
• R33 and R34 form together with the nitrogen atom to which they are bonded a 5-6 membered ring, where in the case of the 6-ring, a CH 2 - group may be replaced by O or S;
• R35, R36, R37, R39 independently of one another are H, (C 1 -C 6) alkyl
• R38, R40, R41 independently of one another are H, (CC 6 ) -alkyl, aryl;
• A represents a - (C (R42) (R43)) m - may be replaced in the 0-2 members can be obtained by an element from the group O, S, N (R44), CO, SO 2;
• R 42, R 43, R 44 independently of one another are H, (C 1 -C 6 -alkyl, aryl;
• R9, R10 independently of one another are H, (CC 8 ) -alkyl, - (CH 2 ) 0 -R45, (CC 4 ) -alkoxy- (C 1 -C 4 ) -alkyl, aryloxy- (C 1 -C 4 ) - alkyl, (C 3 -C 8) -alkenyl, (C 3 -C 8) -alkynyl, CO- (CrCf alkyl, -CO- (CH 2) 0 -R45, CO- (C 1 -C 4) - Alkoxy (C 1 -C 4 ) -alkyl, CO-
• Aryloxy (CC 4 ) alkyl, CO (C 2 -C 8 ) alkenyl, CO (C 2 -C 8 ) alkynyl; or R9 and R10 together with the nitrogen atom to which they are attached are a 4 to 10-membered mono-, bi- or spiro-cyclic ring which may contain, in addition to the nitrogen atom 0 to 4 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein the heterocyclic ring system may additionally be substituted with F , Cl, Br, CF 3 , NO 2 , CN, (-CC 6 ) alkyl, O ⁇ C CsJ-alkyl, (C
• R46, R47, R48, R49, R50, R51, R52 independently of one another are H, (C is Ce ⁇ alkyl;
• R45 is OH, CH (aryl) 2- , 3-12 membered mono- or bicyclic ring which may contain one or more heteroatoms from the group N, O and S and the 3-12 membered ring further substituents such as F, Cl, Br, J, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O-C 1 -C 6 -alkyl, (C 1 -C 4 ) -alkoxy- (C 1 -C 4 ) -alkyl, S- (CC 6 ) -alkyl, (C 1 -C 6 ) -Alkyl, (Cs-C ⁇ -alkenyl, (C 3 -C 8 ) -cycloalkyl, 0- (C 3 -C 8 ) -cycloalkyl, (C 3 -C 8 ) -cycloalkenyl, O- (C 3 -C 8 ) -cycloalkenyl, (
• R (-CC 6 ) -alkyl, (C 0 -C 2 ) -alkylene-aryl, (C 3 -C 8 ) -cycloalkyl, (C 2 -C 6 ) -alkenyl,
• R11, R12, R13, R14, R15 independently of one another H, (CrC- ⁇ J-alkyl
• B is a bond, O, S, SO 2, CO, OCH (R20), N (R23), CH 2, CH 2 CH 2
• R 20, R 23 independently of one another are H, (C 1 -C 6 ) -alkyl
• R1, R2, R3, R4 are independently H, F, Cl, Br, OH, CF 3, N0 2, CN, OCF 3, O- (d-CeJ-alkyl, O- (CC 4) alkoxy (C 1 -C 4 ) -alkyl, S- (CC 6 ) -alkyi, (C 1 -C 6 ) -alkyl, (C 0 -C 2 ) -alkylene-aryl, O- (C 0 -C 2 ) -alkylene-aryl , N (R24) (R25), SO 2 - CH 3) COOH, COO- (CC 6) -alkyl, CON (R26) (R27), N (R28) CO (R29), CO (R32);
• R24, R25, R26, R27, R28, R30 independently of one another are H, (C 1 -C 6) alkyl;
• R29, R32 independently of one another are H, (CC 6 ) -alkyl, aryl;
• R5, R6, R7, R8 are independently H, F, Cl, Br, OH, CF 3, NO 2, CN, OCF 3, O- (C ⁇ Ce alkyl, (C r C6) alkyl, (C 0 -C 2 > alkylene-Aryl, O- (C 0 -C 2 ) -alkylene-aryl,
• R41 (C 1 -C 6 -alkyl, aryl
• A is a chain - (C (R42) (R43)) m - in which 0-2 members may be replaced by an element from the group O, N (R44), CO; m 0, 1, 2, 3, 4;
• R 42, R 43, R 44 independently of one another are H, (C 1 -C 6) -alkyl, aryl;
• R9, R10 independently of one another H, (C ⁇ -C B) alkyl, - (CH 2) 0 -R45, (CC 4) alkoxy- (CC 4) alkyl, aryloxy (CC 4) -alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) alkynyl, CO- (C 1 -C 5 ) alkyl, -CO- (CH 2 ) 0 -R 45, or R 9 and R 10 together with the nitrogen atom to which they are attached are a 4 to 10-membered mono-, bi- or spiro-cyclic ring which, in addition to the nitrogen atom, may contain 0 to 2 additional heteroatoms selected from
• heterocyclic ring system may be additionally substituted with F, Cl, Br, CF 3 , CN, (Ci- C 6 ) alkyl, O- (-C-C 8 ) alkyl, (C 1 -C 4 ) -alkoxy- (C 1 -C) -alkyl, (C 0 -C 2 ) -alkylene-aryl, oxo, CO (R 46), CON (R 47) (R 48), hydroxy, COO (R 49), N (R 50) CO (CC 6 ) alkyl, N (R 51) (R 52) or SO 2 CH 3 ;
• R46, R47, R48, R49, R50, R51, R52 independently of one another are H, (C 1 -C 6 ) -alkyl;
• Heteroatoms from the group N, O and S may contain and the 3-12 membered ring further substituents such as F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O- (C 1 -C 6 ) -Alkyl, (C 1 -C 6 ) -alkyl, (C 2 -C 6 ) -alkenyl, (C 0 -C 2 ) -alkylene-aryl, O- (C 0 -C 2 ) -alkylene-aryl, N (R51 XR52), SO 2 -CH 3 and COOH; and their physiologically acceptable salts.
• substituents such as F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O- (C 1 -C 6 ) -Alkyl, (C 1 -C 6 ) -alkyl, (C 2 -C
• 5-6 membered ring which may contain one or two heteroatoms from the group N, O and S and the 5-6 membered ring further substituents such as F, Cl, Br, NO 2 , CF 3 , OCF 3 , CN, (dC 6 ) -alkyl, O- (CC 6 ) -alkyl can carry;
• B is a bond, O, S, CO, OCH 2 , N (R 23), CH 2 ;
• R 23 is H, (C 1 -C 6 ) -alkyl
• R 1, R 2, R 3, R 4, independently of one another, are H, F, Cl, Br, CF 3) O-C 1 -alkyl, (C 1 -C 6 ) -alkyl;
• R5, R6, R7, R8 are independently H, F, Cl, Br, OH, CF 3, NO 2, CN, OCF 3, O- (dC 6) alkyl
• A is a chain - (C (R42) (R43)) m -, in which one member can be replaced by a
• R 42, R 43, R 44 independently of one another are H, (CC 6 ) -alkyl, aryl;
• R9, R10 independently of one another are H, (C 1 -C 8 ) -alkyl, - (CH 2 ) 0 -R45, CO- (CC 8 ) -
• R 9 and R 10 together with the nitrogen atom to which they are attached form a mono-, bi- or spiro-4 to 10-membered cyclic ring which, in addition to the nitrogen atom, may contain from 0 to 2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur "where the heterocyclic ring system may additionally be substituted by F, (C 1 -C 6) -alkyl, O- (C 1 -C 8 ) alkyl, oxo, CO (R46), CON (R47) (R48), hydroxy, N (R50) CO (CC 6) alkyl or
• R46, R47, R48, R50, R51, R52 independently of one another are H, (C 1 -C 6 ) -alkyl
• R45 OH 5-10 membered mono- or bicyclic ring, one or two
• Heteroatoms from the group N, O and S may contain and the 3-12 membered ring further substituents such as F, Cl, Br, OH, CF 3 , oxo, O- (C 1 -C 6 ) alkyl, (dC 6 ) - Alkyl, (C 0 -C 2 ) -alkylene-aryl, O- (C 0 -C 2 ) -alkylene-aryl or
• Another particular class within the particularly preferred compounds I form the molecules for which applies R5, R6, R7, R8 H.
• Another particular class within the particularly preferred compounds I are the molecules in which A and B are each arranged in the para position to the central heterocycle.
• radicals or substituents can occur more than once in the compounds of the formula I, for example - (CH 2 ) 0 -R45, then they may all, independently of one another, have the meanings indicated and be identical or different.
• the invention relates to compounds of the formula I, in the form of their racemates, enantiomerically enriched mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
• alkyl, alkenyl and alkynyl radicals in the substituents R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 , R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44 , R45, R46, R46, R47, R48, R49, R50, R51 and R52 may be straight-chained, branched or optionally halogenated.
• aryl is meant a phenyl or naphthyl group.
• Mono-, bi- or spiro-cyclic rings can be saturated, partially saturated or unsaturated and also bridged.
• Suitable pharmaceutically acceptable salts are particularly suitable for medical applications because of their higher water solubility compared to the starting or basic compounds. These salts must have a pharmaceutically acceptable anion or cation.
• Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and also organic acids, such as, for example, acetic acid, Benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and tartaric trifluoroacetic acid.
• the chloro salt is used in a particularly preferred manner.
• Suitable pharmaceutically acceptable basic salts are ammoni
• Salts with a non-pharmaceutically acceptable anion are also within the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and / or for use in nontherapeutic, for example, in vitro applications.
• physiologically functional derivative refers to any physiologically acceptable derivative of a Formula 1 compound of the invention, e.g. an ester which, when administered to a mammal, e.g. humans, is able to form (directly or indirectly) a compound of formula I or an active metabolite thereof.
• the physiologically functional derivatives also include prodrugs of the compounds according to the invention.
• prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may or may not be effective.
• the compounds of the invention may also be in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of the invention are within the scope of the invention and are a further aspect of the invention.
• the daily dose is in the range of 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of body weight, eg 3-10 mg / kg / day.
• an intravenous dose may range from 0.3 mg to 1.0 mg / kg, which may conveniently be administered as an infusion of 10 ng to 10 ng per kilogram per minute. Suitable infusion solutions for these purposes, for example
• Single doses may e.g. from 1 mg to 10 g of the active ingredient.
• vials for injections, and orally administrable unit dose formulations, such as tablets or capsules may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. in the
• the abovementioned weights are based on the weight of the free compound on which the salt is based.
• the compounds of the formula (I) may themselves be used as the compound, but they are preferably in the form of a compatible carrier
• the carrier must of course be compatible in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient.
• the carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, from 0.05% to
• composition 25 may contain 95% by weight of the active substance.
• Other pharmaceutically active substances may also be present, including further compounds according to formula (I).
• the pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which consist essentially in that the constituents are mixed with pharmacologically acceptable carriers.
• compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case is the nature and severity of the treatment State and on the nature of the particular compound used according to formula (I) is dependent.
• coated formulations and coated slow release formulations are within the scope of the invention. Preference is given to acid and enteric formulations. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
• Suitable pharmaceutical compounds for oral administration may be in separate units, such as capsules, cachets, lozenges or tablets, each containing a certain amount of the compound of formula (I); as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
• these compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the carrier (which may consist of one or more additional ingredients).
• the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is molded, if necessary.
• a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients.
• Compressed tablets may be prepared by tableting the compound in free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or surfactant / dispersing agent in a suitable machine.
• Shaped tablets can by molding the powdered, moistened with an inert liquid diluent compound can be prepared in a suitable machine.
• compositions suitable for peroral (sublingual) administration include lozenges containing a compound of formula (I) having a flavor, usually sucrose and gum arabic or tragacanth, and lozenges containing the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
• Suitable pharmaceutical compositions for parenteral administration preferably comprise sterile aqueous preparations of a compound according to formula (I) which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions of the invention generally contain from 0.1% to 5% by weight of the active compound.
• Suitable pharmaceutical compositions for rectal administration are preferably as single dose suppositories. These can be prepared by mixing a compound according to formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
• Suitable pharmaceutical compositions for topical application to the skin are preferably as an ointment, cream, lotion, paste, spray, aerosol or oil.
• Vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more of these substances can be used as the carrier.
• the active ingredient is generally present at a level of from 0.1% to 15% by weight of the composition, for example from 0.5% to 2%. Tränsdermale administration is possible.
• Suitable pharmaceutical compositions for transdermal applications may exist as single patches suitable for long-term close contact with the epidermis of the patient. Such patches suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesive or dispersed in a polymer.
• a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
• the active ingredient can be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
• the compounds of formula 1 are distinguished by favorable effects on lipid metabolism, in particular they are suitable for weight loss and after weight reduction to obtain a reduced weight in mammals and as anorectic.
• the compounds are characterized by their low toxicity and their low side effects.
• the compounds can be used alone or in combination with other weight-reducing or anorectic agents.
• Such other anorectic agents are e.g. in the Red List, Chapter 01 under weight loss / appetite suppressants and may also include such agents that increase the energy expenditure of the organism and thus lead to a weight loss or even those that affect the general metabolism of the organism so that an increased calorie intake not An increase in fat deposits and a normal calorie intake leads to a reduction in fat deposits of the organism.
• the compounds are suitable for the prophylaxis and in particular for the treatment of overweight or obesity.
• the compounds are furthermore suitable for the prophylaxis and in particular for the treatment of type II diabetes, atherosclerosis and for the normalization of lipid metabolism and for the treatment of hypertension.
• the compounds act as MCH antagonists and are also useful in the treatment of disorders of sensation and other psychiatric indications, such as
• the compounds of the formula I can be administered in combination with one or more further pharmacologically active substances, for example selected from antidiabetics, antiadipositas, antihypertensive agents, lipid lowering agents and agents for the treatment and / or prevention of complications caused by diabetes or associated with diabetes.
• antidiabetics include insulins, amylin, GLP-1 and GLP-2 derivatives such as e.g. those disclosed in WO 98/08871 by Novo Nordisk A / S and orally active hypoglycemic agents.
• the orally active hypoglycemic agents preferably include sulphonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, potassium channel openers, e.g. those disclosed in WO 97/26265 and WO 99/03861 by Novo Nordisk A / S, insulin sensitizers, insulin receptor kinase activators, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and / or glycogenolysis, e.g. Inhibitors of glycogen phosphorylase, modulators of glucose uptake and
• lipid metabolism altering compounds such as antihyperlipidemic agents and antilipidemic agents, e.g. HMGCoA reductase inhibitors, cholesterol transport / cholesterol uptake inhibitors, bile acid reabsorption inhibitors or microsomal triglyceride transfer protein (MTP) inhibitors, food intake reducing compounds, PPAR and RXR agonists, and ATP-dependent drugs Potassium channel of beta cells act.
• antihyperlipidemic agents and antilipidemic agents e.g. HMGCoA reductase inhibitors, cholesterol transport / cholesterol uptake inhibitors, bile acid reabsorption inhibitors or microsomal triglyceride transfer protein (MTP) inhibitors
• MTP microsomal triglyceride transfer protein
• the present compounds are administered in combination with insulin.
• the present compounds are administered in combination with a sulphonylurea such as tolbutamide, glibenclamide, glimepiride, glipizide, gliquidone, glisoxepid, glibornuride or gliclazide.
• the present compounds are administered in combination with a biguanide such as metformin.
• the subject compounds are administered in combination with a meglitinide such as repaglinide.
• the present compounds are used in combination with a thiazolidinedione, such as troglizzone, ciglitazone, pioglitazone, rosiglitazone or those described in WO 97/41097 by Dr. med. Reddy's Research Foundation disclosed compounds, particularly 5 - [[4 - [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy) phenyl] methyl] -2,4-thiazolidinedione
• the present compounds are administered in combination with a ⁇ -glucosidase inhibitor such as miglitol or acarbose.
• the present compounds are administered in combination with an agent that acts on the ATP-dependent potassium channel of the beta cells, such as e.g. Tolbutamide, glibenclamide, glimepiride, glipizide, gliclazide or repaglinide.
• an agent that acts on the ATP-dependent potassium channel of the beta cells such as e.g. Tolbutamide, glibenclamide, glimepiride, glipizide, gliclazide or repaglinide.
• the subject compounds are used in combination with an antihyperlidemic agent or an antilipidemic agent, such as an anti-lipidemic agent.
• an antihyperlidemic agent or an antilipidemic agent such as an anti-lipidemic agent.
• the present compounds are used in combination with more than one of the aforementioned compounds, eg in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin and troglazzone, Insulin and lovastatin, etc. administered.
• the compounds according to the invention can be administered in combination with one or more antiadipositas or appetite regulating active ingredients.
• Such agents may be selected from the group consisting of CART agonists, NPY antagonists, MC4 agonists, orexin antagonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,?
• Agonists MSH (melanocyte stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed sertonine and norepinephrine reuptake inhibitors, 5HT modulators, MAO inhibitors, bombesin agonists, galanin antagonists, growth hormone, Growth hormone releasing compounds, TRH agonists, modulators of decoupling proteins 2 or 3, leptin agonists, dopamine agonists (bromocriptine, doprexin), lipase / amylase inhibitors, antagonists of cannabinoid receptor 1, modulators of acylation stimulating protein ( ASP), PPAR modulators, RXR modulators, hCNTF mimetics or TR -? - agonists.
• MSH melanocyte stimulating hormone
• CCK agonists serotonin reuptake inhibitors
• mixed sertonine and norepinephrine reuptake inhibitors 5HT modulators
• MAO inhibitors bombes
• the anti-adiposity is leptin or modified leptin.
• the anti-adiposity is dexamphetamine or amphetamine. In another embodiment, the anti-adiposity is fenfluramine or
• the anti-adiposity is sibutramine or the mono- and bis-demethylated active metabolites of sibutramine.
• the anti-obesity agent is orlistat.
• the anti-obesity agent is mazindol, diethylpropion
• the present compounds may be administered in combination with one or more antihypertensive agents.
• antihypertensive agents are beta blockers such as alprenolol, atenol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as e.g.
• 25 benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and rampril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and alpha-blockers such as doxazosin, urapidil, prazosin and terazosin.
• Remington The Science and Practice of Pharmacy, 19th Ed., Gennaro, eds., Mack Publishing Co., Easton, PA,
• MCH melanin-concentrating hormone
• the host used for the transfection was a transformed HEK cell line called "PEAK stable cells" (likewise from EDGE Biosystems)
• the functional measurements of the cellular calcium flux after addition of agonist (MCH) in the presence of ligand according to the invention were carried out with the aid of the FLIPR apparatus of the company. Molecular Devices (USA), using device manufacturer's instructions
• Exemplary compounds showed IC 50 values on the order of 0.01 to> 10 ⁇ M.
• the anorectic effect was tested on female NMRI mice. After 17 hours of food deprivation was via a gavage, the test preparation administered. In individual housing and with free access to drinking water, the animals were offered condensed milk 30 minutes after preparation. Condensed milk consumption was determined for half an hour for 7 hours and the general condition of the animals was observed. The measured milk consumption was compared with the vehicle-treated control animals. Table 1: Anorectic effect, measured as a reduction of cumulated milk consumption treated compared to control animals.
• Example 5 1 - [4- (2-Phenethylamino-ethoxy) -phenyl] -3- (4-phenoxyphenyl) -1,3-dihydro-imidazol-2-one
• the compound was prepared by zinc dust reduction of N, N, N'-trimethyl-N'- (4-nitro-phenyl) -ethane-1,2-diamine analogously to the procedure in Example 3. This gave the product with a molecular weight of 193 , 29 (CnH 19 N 3 ); MS (ESI): 194 ([M + H] + ).
• Example 165 1 (4-Cyclopentyloxy-phenyl) -3- ⁇ 4 - [(2-imidazol-1-yl-ethyl) -methyl-amino] -phenyl ⁇ -1, 3-dihydro-imidazol-2-one
• Example 171 The compound was prepared as described in Example 171 by hydrogenating 1- (4-cyclopropylmethoxyphenyl) -3- [4- (2-dimethylamino-ethoxy) -phenyl] -1,3-dihydroimidazol-2-one. This gave the product with the molecular weight 395.51 (CssHzgNsOs); MS (ESI): 396 ([M + H] + ).
• Example 222 1 - ( ⁇ 4- [2-Oxo-3- (4-phenoxy-phenyl) -2,3-dihydro-imidazol-1-yl] -phenylcarbamoyl ⁇ -ethyl) -piperidine-4-carboxylic acid ethyl ester

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Child & Adolescent Psychology (AREA)
• Psychiatry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=30128364

Family Applications (2)

Family Applications After (1)

Country Status (14)

Cited By (14)

Families Citing this family (25)

Family Cites Families (11)

• 2002
  • 2002-07-25 DE DE10233817A patent/DE10233817A1/de not_active Withdrawn
• 2003
  • 2003-07-15 WO PCT/EP2003/007639 patent/WO2004012648A2/de not_active Ceased
  • 2003-07-15 AU AU2003257465A patent/AU2003257465A1/en not_active Abandoned
  • 2003-07-18 MX MXPA05001048A patent/MXPA05001048A/es active IP Right Grant
  • 2003-07-18 BR BR0312916-0A patent/BR0312916A/pt not_active IP Right Cessation
  • 2003-07-18 AT AT03771060T patent/ATE535513T1/de active
  • 2003-07-18 JP JP2004523753A patent/JP4568113B2/ja not_active Expired - Fee Related
  • 2003-07-18 EP EP03771060A patent/EP1551810B1/de not_active Expired - Lifetime
  • 2003-07-18 CA CA002493924A patent/CA2493924A1/en not_active Abandoned
  • 2003-07-18 AU AU2003251001A patent/AU2003251001B9/en not_active Ceased
  • 2003-07-18 WO PCT/EP2003/007891 patent/WO2004011438A1/de not_active Ceased
  • 2003-07-21 PE PE2003000725A patent/PE20040702A1/es not_active Application Discontinuation
  • 2003-07-23 AR AR20030102644A patent/AR040514A1/es unknown
  • 2003-07-23 MY MYPI20032759A patent/MY142551A/en unknown
  • 2003-07-23 TW TW092120029A patent/TW200408627A/zh unknown
• 2005
  • 2005-01-17 IL IL166471A patent/IL166471A/en not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events